Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oryzon GenomicsORYZF -0.30%33 3-Year EPS without NRI Growth Rate is 23.30% as of Jun. 2026, which is 163% above its 10-year median of 8.85. GuruFocus rates ORYZF with a GF Scoreâ„¢ of 33/100. Among 1,162 Biotechnology companies, Oryzon Genomics ranks better than 58.61% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 23.30% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 13.10% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 4.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 12 years, the highest 3-Year average EPS without NRI Growth Rate of Oryzon Genomics was 25.50% per year. The lowest was -42.10% per year. And the median was 8.85% per year.
Oryzon Genomics (OTCPK:ORYZF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Oryzon Genomics 3-Year EPS without NRI Growth Rate Related Terms
ORYZF vs VRTX, REGN, RVMD: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Oryzon Genomics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oryzon Genomics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oryzon Genomics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Oryzon Genomics's 3-Year EPS without NRI Growth Rate falls into.
Oryzon Genomics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 23.30% mean?
Oryzon Genomics (ORYZF) has a 3-Year EPS without NRI Growth Rate of 23.30% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Oryzon Genomics and its competitors. This is 163% above median its historical median of 8.85. According to the industry distribution chart, Oryzon Genomics ranks #481 out of 1162 companies in the Biotechnology industry, placing it in the top 41.4%.
Is Oryzon Genomics' 3-Year EPS without NRI Growth Rate too high?
Oryzon Genomics' current 3-Year EPS without NRI Growth Rate of 23.30% is 163% above median its 10-year median of 8.85. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Oryzon Genomics' value of 23.30% is 43.8% above this industry median. Based on the distribution chart, Oryzon Genomics ranks #481 out of 1162 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oryzon Genomics has a GF Scoreâ„¢ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oryzon Genomics ranks #481 out of 1162 companies for 3-Year EPS without NRI Growth Rate. This puts Oryzon Genomics in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Oryzon Genomics' value of 23.30% is 43.8% above this benchmark. While the company's 10-year median is 8.85 vs. the industry median of 16.20, Oryzon Genomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,162 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oryzon Genomics's current 3-Year EPS without NRI Growth Rate of 23.30% is 43.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Oryzon Genomics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oryzon Genomics's current 3-Year EPS without NRI Growth Rate is 23.30%, which is 163% above median its own 10-year median of 8.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (ORYZF) has a current 3-Year EPS without NRI Growth Rate of 23.30%. The current 3-Year EPS without NRI Growth Rate is 23.30%, which is 163% above median its 10-year median of 8.85 and 43.8% above the Biotechnology industry median of 16.20. Oryzon Genomics' overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Oryzon Genomics (ORYZF), the current 3-Year EPS without NRI Growth Rate is 23.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
33GF Score
Get the complete analysis for ORYZF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORYZF has been successfully added to your 
